Results 51 to 60 of about 30,157 (233)
BMC Health Services Research, 2019 Background The pharmaceutical industry in Iran is influenced by various parameters such as internal factors caused by the financial information of each economic unit and external factors including major economic and non-economic variables.
Mohammadreza Masoumi +3 more
doaj +1 more source
Asia-Pacific Journal of Chemical Engineering, EarlyView.ABSTRACT Lipid‐based nanoparticles (LNPs) are favored for drug delivery because of their low toxicity, high biocompatibility, ability to self‐assemble into nanoparticles, and ability to enhance drug bioavailability, thereby improving drug release modulation and pharmacokinetics.
Gulizar Caliskan +3 more
wiley +1 more source
The value of medicine in improving the quality of care
South African Family Practice, 2007 Patients expect the provision of quality care from the healthcare system, whether they are in the public sector or the private sector. One method amongst many of ensuring the provision of quality care is through the use of medicine.
Joao L. Carapinha
doaj +1 more source
Exergy and Economic Analysis of Hybrid Mechanical Vapor Compression and Membrane Distillation
Asia-Pacific Journal of Chemical Engineering, EarlyView.ABSTRACT Hybridization of two or more desalination processes has been identified as an attractive option for improved energy efficiency and recovery rate. To appropriately assess the performance enhancement of hybrid desalination systems, an integrated approach for energy, exergy, economic, and environmental investigations should be adopted. This study
Emad Ali, Jamel Orfi
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Organizational-economic aspects of innovative technologies in the field of pharmacy
RUDN Journal of Medicine, 2011 This article presents the basic directions of scientific researches of the department of management and economics in pharmacy in the field of use of innovative technologies, such as research of expenses for medicinal therapy of various diseases ...
E E Loskutova +4 more
doaj
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Patient Preference and Adherence, 2021 Jędrzej Lewicki,1 Urszula Religioni,2 Piotr Merks3 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland; 2Collegium of Business Administration, Warsaw School of Economics, Warsaw, Poland ...
Lewicki J, Religioni U, Merks P
doaj
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source